Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-β1 expression

Choi, Hoo‐Kyun; Pokharel, Yuba Raj; Lim, Sung Chul; Han, Hyo-Kyung; Ryu, Chang Seon; Kim, Sang Kyum; Kwak, Mi Kyong; Kang, Keon Wook

doi:10.1016/j.taap.2009.07.030

Cited by 97 publications

(64 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…and 3 ('Did your erection last long enough for you to have successful intercourse?'). EF was categorized as follows using the IIEF-5 total scores: no ED (22)(23)(24)(25), mild ED (17-21), mild to moderate ED (12)(13)(14)(15)(16), moderate ED (8-11) and severe ED (5-7). 19,20 Presence and severity of painful erections was determined on a conventional 10-point visual analog pain scale (VAS) score ranging from 0 to 10, with 0 being no pain and 10 being severe pain.…”

Section: Evaluationsmentioning

confidence: 99%

“…'; (iii) treatment satisfaction as assessed using patient versions of the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire; 26 and (iv) improvement in penile artery indices. Follow-up points were weeks 4,8,12,16,20,24, and 4 weeks after stopping treatment. The following variables were assessed at each follow-up visit: EF by IIEF-5 and SEP diary questions 2 and 3; plaque characteristics by ultrasound and X-ray; subjective changes in penile curvature by sketch and pain during erection by VAS; mean sexual intercourse per week, responses to GAQ and treatment satisfaction by EDITS.…”

Section: Outcome Measuresmentioning

confidence: 99%

“…16 Nrf2 overexpression itself reduces the basal expression of a-smooth muscle actin and TGF-b1. 16 Therefore, CoQ 10 -induced Nrf2 activation may suppress TGF-b1 expression. This study is the first prospective, double-blind, placebo-controlled randomized study on the effects of CoQ 10 supplementation in men with early chronic PD.…”

Section: Introductionmentioning

confidence: 95%

“…It has been reported that solubilized CoQ 10 suppresses the expression of TGF-b1 induced by dimethylnitrosamine in mouse liver and mouse embryonic fibroblast cells. 16 In addition, CoQ 10 activates NF-E2-related factor-2 (Nrf2). 16 Nrf2 overexpression itself reduces the basal expression of a-smooth muscle actin and TGF-b1.…”

Section: Introductionmentioning

confidence: 99%

“…16 In addition, CoQ 10 activates NF-E2-related factor-2 (Nrf2). 16 Nrf2 overexpression itself reduces the basal expression of a-smooth muscle actin and TGF-b1. 16 Therefore, CoQ 10 -induced Nrf2 activation may suppress TGF-b1 expression.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study

Safarinejad¹

2010

Int J Impot Res

View full text Add to dashboard Cite

Section: Evaluationsmentioning

confidence: 99%

Section: Outcome Measuresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study

Safarinejad¹

2010

Int J Impot Res

View full text Add to dashboard Cite

The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: An open label pilot study

Mezawa¹,

Takemoto²,

Onishi³

et al. 2012

BioFactors

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ10) provides the energy for vital cellular functions and is known to act as an antioxidant. We conducted an open label study to examine the clinical effects of supplementation of the reduced form of CoQ10, ubiquinol, in addition to conventional glucose-lowering agents in patients with type 2 diabetes. Nine subjects (3 males and 6 females) with type 2 diabetes and receiving conventional medication were recruited. The subjects were assigned to receive an oral dose of 200 mg ubiquinol daily for 12 weeks. The effect of ubiquinol on blood pressure, lipid profile, glycemic control, oxidative stress, and inflammation were examined before and after ubiquinol supplementation. In addition, five healthy volunteers were also assigned to receive an oral dose of 200 mg ubiquinol daily for 4 weeks to examine the effects of ubiquinol on insulin secretion. In patients with diabetes, there were no differences with respect to blood pressure, lipid profile, oxidative stress marker, and inflammatory markers. However, there were significant improvements in glycosylated hemoglobin (53.0 ± 4.3 to 50.5 ± 3.7 mmol/mol, P = 0.01) (7.1 ± 0.4 to 6.8 ± 0.4%, P = 0.03). In healthy volunteers, the insulinogenic index (0.65 ± 0.29 to 1.23 ± 0.56, P = 0.02) and the ratio of proinsulin to insulin were significantly improved (3.4 ± 1.8 to 2.1 ± 0.6, P = 0.03). The results of our study are consistent with the suggestion that the supplementation of ubiquinol in subjects with type 2 diabetes, in addition to conventional antihyperglycemic medications, improves glycemic control by improving insulin secretion without any adverse effects

show abstract

Fabrication of a decellularized liver matrix–based hepatic patch for the repair of CCl4‐induced liver injury

Wu,

Hsieh,

Yin

et al. 2024

Biotechnology Journal

View full text Add to dashboard Cite

This article primarily introduces a new treatment for liver fibrosis/cirrhosis. We developed a hepatic patch by combining decellularized liver matrix (DLM) with the hepatocyte growth factor (HGF)/heparin–complex and evaluated its restorative efficacy. In vitro prophylactic results, the HGF/heparin–DLM patches effectively mitigated CCl4‐induced hepatocyte toxicity and restored the cytotoxicity levels to the baseline levels by day 5. Furthermore, these patches restored albumin synthesis of injured hepatocytes to more than 70% of the normal levels within 5 days. In vitro therapeutic results, the urea synthesis of the injured hepatocytes reached 91% of the normal levels after 10 days of culture, indicating successful restoration of hepatic function by the HGF/heparin–DLM patches in both prophylactic and therapeutic models. In vivo results, HGF/heparin–DLM patches attached to the liver and gut exhibited a significant decrease in collagen content (4.44 times and 2.77 times, respectively) and an increase in glycogen content (1.19 times and 1.12 times, respectively) compared to the fibrosis group after 1 week, separately. In summary, liver function was restored and inflammation was inhibited through the combined effects of DLM and the HGF/heparin–complex in fibrotic liver. The newly designed hepatic patch holds promise for both in vitro and in vivo regeneration therapy and preventive health care for liver tissue engineering.

show abstract

Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-β1 expression

Cited by 97 publications

References 48 publications

Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study

Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study

The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: An open label pilot study

Fabrication of a decellularized liver matrix–based hepatic patch for the repair of CCl4‐induced liver injury

Contact Info

Product

Resources

About